{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,14]],"date-time":"2026-05-14T23:08:14Z","timestamp":1778800094558,"version":"3.51.4"},"reference-count":38,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T00:00:00Z","timestamp":1777593600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T00:00:00Z","timestamp":1777593600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/501100004374","name":"Chongqing Medical University","doi-asserted-by":"publisher","award":["W0126"],"award-info":[{"award-number":["W0126"]}],"id":[{"id":"10.13039\/501100004374","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","seizure-journal.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Seizure: European Journal of Epilepsy"],"published-print":{"date-parts":[[2026,5]]},"DOI":"10.1016\/j.seizure.2026.04.002","type":"journal-article","created":{"date-parts":[[2026,4,5]],"date-time":"2026-04-05T11:20:21Z","timestamp":1775388021000},"page":"84-92","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["Adjunctive antiepileptic efficacy and safety study of mTOR inhibitors in children with tuberous sclerosis complex"],"prefix":"10.1016","volume":"138","author":[{"given":"Ran","family":"Ding","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Linxue","family":"Meng","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Siqi","family":"Hong","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yi","family":"Guo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Min","family":"Cheng","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yue","family":"Hu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yuanyuan","family":"Luo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Li","family":"Jiang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8115-5068","authenticated-orcid":false,"given":"Lingling","family":"Xie","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.seizure.2026.04.002_bib0001","doi-asserted-by":"crossref","first-page":"1490","DOI":"10.1016\/S0140-6736(05)78872-3","article-title":"Prevalence of tuberous sclerosis estimated by capture-recapture analysis","volume":"351","author":"O'Callaghan","year":"1998","journal-title":"Lancet"},{"key":"10.1016\/j.seizure.2026.04.002_bib0002","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1186\/s13023-024-03495-1","volume":"20","author":"Driedger","year":"2025","journal-title":"Orphanet J Rare Dis"},{"key":"10.1016\/j.seizure.2026.04.002_bib0003","doi-asserted-by":"crossref","first-page":"176","DOI":"10.1038\/s41419-024-06547-3","article-title":"mTOR pathway occupies a central role in the emergence of latent cancer cells","volume":"15","author":"Aleksandrova","year":"2024","journal-title":"Cell Death and Disease"},{"key":"10.1016\/j.seizure.2026.04.002_bib0004","doi-asserted-by":"crossref","DOI":"10.3390\/ijms26157244","article-title":"The activation of the microglial NLRP3 inflammasome is involved in tuberous sclerosis complex-related neuroinflammation","volume":"26","author":"Ding","year":"2025","journal-title":"Int J Mol Sci"},{"key":"10.1016\/j.seizure.2026.04.002_bib0005","doi-asserted-by":"crossref","DOI":"10.1016\/j.bbamcr.2025.119986","article-title":"Inhibition of NAMPT as a therapeutic strategy to suppress tumor growth in lymphangioleiomyomatosis","volume":"1872","author":"Fard","year":"2025","journal-title":"Biochim Biophys Acta Mol Cell Res"},{"key":"10.1016\/j.seizure.2026.04.002_bib0006","doi-asserted-by":"crossref","first-page":"10719","DOI":"10.2147\/DDDT.S525749","article-title":"Canagliflozin as a potential preclinical therapy for tuberous sclerosis complex: inhibition of Tsc2 (-\/-) cell proliferation via cell cycle arrest and mitochondrial dysfunction","volume":"19","author":"Ye","year":"2025","journal-title":"Drug Des Devel Ther"},{"key":"10.1016\/j.seizure.2026.04.002_bib0007","doi-asserted-by":"crossref","first-page":"657","DOI":"10.1016\/S0140-6736(08)61279-9","article-title":"Tuberous sclerosis","volume":"372","author":"Curatolo","year":"2008","journal-title":"Lancet"},{"key":"10.1016\/j.seizure.2026.04.002_bib0008","doi-asserted-by":"crossref","DOI":"10.1038\/nrdp.2016.35","article-title":"Tuberous sclerosis complex","volume":"2","author":"Henske","year":"2016","journal-title":"Nat Rev Dis Primers"},{"key":"10.1016\/j.seizure.2026.04.002_bib0009","doi-asserted-by":"crossref","first-page":"1236","DOI":"10.1111\/j.1528-1167.2009.02474.x","article-title":"The natural history of epilepsy in tuberous sclerosis complex","volume":"51","author":"CJ","year":"2010","journal-title":"Epilepsia"},{"key":"10.1016\/j.seizure.2026.04.002_bib0010","doi-asserted-by":"crossref","first-page":"838","DOI":"10.1111\/j.1365-2788.2009.01208.x","article-title":"From mTOR to cognition: molecular and cellular mechanisms of cognitive impairments in tuberous sclerosis","volume":"53","author":"Ehninger","year":"2009","journal-title":"J Intell Disability Res"},{"key":"10.1016\/j.seizure.2026.04.002_bib0011","doi-asserted-by":"crossref","DOI":"10.3389\/fneur.2022.704978","article-title":"Antiepileptic effect and safety profile of rapamycin in pediatric patients with tuberous sclerosis complex","volume":"13","author":"Sadowski","year":"2022","journal-title":"Front Neurol"},{"key":"10.1016\/j.seizure.2026.04.002_bib0012","doi-asserted-by":"crossref","first-page":"140","DOI":"10.1056\/NEJMoa063564","article-title":"Sirolimus for angiomyolipoma in tuberous sclerosis complex or lymphangioleiomyomatosis","volume":"358","author":"Bissler","year":"2008","journal-title":"N Engl J Med"},{"key":"10.1016\/j.seizure.2026.04.002_bib0013","doi-asserted-by":"crossref","first-page":"132","DOI":"10.1016\/j.seizure.2025.06.017","article-title":"Pediatric refractory epilepsy related to tuberous sclerosis complex: a retrospective-cohort study of diagnosis and treatment","volume":"131","author":"Lin","year":"2025","journal-title":"Seizure"},{"key":"10.1016\/j.seizure.2026.04.002_bib0014","doi-asserted-by":"crossref","first-page":"905","DOI":"10.1126\/science.1715094","article-title":"Targets for cell cycle arrest by the immunosuppressant rapamycin in yeast","volume":"253","author":"Heitman","year":"1991","journal-title":"Science"},{"key":"10.1016\/j.seizure.2026.04.002_bib0015","doi-asserted-by":"crossref","first-page":"444","DOI":"10.1002\/ana.21331","article-title":"Rapamycin prevents epilepsy in a mouse model of tuberous sclerosis complex","volume":"63","author":"Zeng","year":"2008","journal-title":"Ann Neurol"},{"key":"10.1016\/j.seizure.2026.04.002_bib0016","doi-asserted-by":"crossref","first-page":"477","DOI":"10.1177\/0883073808324535","article-title":"Rapamycin reduces seizure frequency in tuberous sclerosis complex","volume":"24","author":"Muncy","year":"2009","journal-title":"J Child Neurol"},{"key":"10.1016\/j.seizure.2026.04.002_bib0017","doi-asserted-by":"crossref","first-page":"3029","DOI":"10.1111\/epi.17099","article-title":"Adjunctive everolimus therapy for tuberous sclerosis complex-associated refractory seizures: results from the postextension phase of EXIST-3","volume":"62","author":"Franz","year":"2021","journal-title":"Epilepsia"},{"key":"10.1016\/j.seizure.2026.04.002_bib0018","article-title":"Everolimus as adjunctive treatment in tuberous sclerosis complex-associated epilepsy in children","volume":"66","author":"Svarrer","year":"2019","journal-title":"Dan Med J"},{"key":"10.1016\/j.seizure.2026.04.002_bib0019","doi-asserted-by":"crossref","first-page":"2153","DOI":"10.1016\/S0140-6736(16)31419-2","article-title":"Adjunctive everolimus therapy for treatment-resistant focal-onset seizures associated with tuberous sclerosis (EXIST-3): a phase 3, randomised, double-blind, placebo-controlled study","volume":"388","author":"French","year":"2016","journal-title":"Lancet"},{"key":"10.1016\/j.seizure.2026.04.002_bib0020","doi-asserted-by":"crossref","first-page":"495","DOI":"10.1016\/S2352-4642(18)30099-3","article-title":"Adjunctive everolimus for children and adolescents with treatment-refractory seizures associated with tuberous sclerosis complex: post-hoc analysis of the phase 3 EXIST-3 trial","volume":"2","author":"Curatolo","year":"2018","journal-title":"Lancet Child Adolesc Health"},{"key":"10.1016\/j.seizure.2026.04.002_bib0021","doi-asserted-by":"crossref","first-page":"931","DOI":"10.1007\/s40120-023-00476-7","article-title":"Effect of mTOR inhibitors in epilepsy treatment in children with tuberous sclerosis complex under 2 years of age","volume":"12","author":"\u015amia\u0142ek","year":"2023","journal-title":"Neurol Ther"},{"key":"10.1016\/j.seizure.2026.04.002_bib0022","doi-asserted-by":"crossref","first-page":"1011","DOI":"10.1212\/WNL.0000000000003077","article-title":"Sirolimus for epilepsy in children with tuberous sclerosis complex: a randomized controlled trial","volume":"87","author":"Overwater","year":"2016","journal-title":"Neurology"},{"key":"10.1016\/j.seizure.2026.04.002_bib0023","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1016\/j.pediatrneurol.2013.08.002","article-title":"Tuberous sclerosis complex surveillance and management: recommendations of the 2012 International Tuberous Sclerosis Complex Consensus Conference","volume":"49","author":"Krueger","year":"2013","journal-title":"Pediatr Neurol"},{"key":"10.1016\/j.seizure.2026.04.002_bib0024","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1016\/j.pediatrneurol.2013.08.001","article-title":"Tuberous sclerosis complex diagnostic criteria update: recommendations of the 2012 Iinternational Tuberous Sclerosis Complex Consensus Conference","volume":"49","author":"Northrup","year":"2013","journal-title":"Pediatr Neurol"},{"key":"10.1016\/j.seizure.2026.04.002_bib0025","series-title":"N. Common terminology criteria for adverse events (CTCAE) common terminology criteria for adverse events (CTCAE) v5.0","year":"2017"},{"key":"10.1016\/j.seizure.2026.04.002_bib0026","doi-asserted-by":"crossref","first-page":"5422","DOI":"10.1523\/JNEUROSCI.0955-08.2008","article-title":"Response of a neuronal model of tuberous sclerosis to mammalian target of rapamycin (mTOR) inhibitors: effects on mTORC1 and akt signaling lead to improved survival and function","volume":"28","author":"Meikle","year":"2008","journal-title":"J Neurosci"},{"key":"10.1016\/j.seizure.2026.04.002_bib0027","doi-asserted-by":"crossref","first-page":"679","DOI":"10.1002\/ana.23960","article-title":"Everolimus treatment of refractory epilepsy in tuberous sclerosis complex","volume":"74","author":"Krueger","year":"2013","journal-title":"Ann Neurol"},{"key":"10.1016\/j.seizure.2026.04.002_bib0028","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1186\/s13023-019-1077-6","article-title":"Safety and efficacy of mTOR inhibitor treatment in patients with tuberous sclerosis complex under 2\u2009years of age - a multicenter retrospective study","volume":"14","author":"Saffari","year":"2019","journal-title":"Orphanet J Rare Dis"},{"key":"10.1016\/j.seizure.2026.04.002_bib0029","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1016\/j.yebeh.2018.05.039","article-title":"The role of mTOR inhibitors in preventing epileptogenesis in patients with TSC: current evidence and future perspectives","volume":"91","author":"Schubert-Bast","year":"2019","journal-title":"Epilepsy Behav"},{"key":"10.1016\/j.seizure.2026.04.002_bib0030","doi-asserted-by":"crossref","first-page":"377","DOI":"10.1186\/s13023-023-02982-1","article-title":"Effectiveness and safety of everolimus treatment in patients with tuberous sclerosis complex in real-world clinical practice","volume":"18","author":"Cockerell","year":"2023","journal-title":"Orphanet J Rare Dis"},{"key":"10.1016\/j.seizure.2026.04.002_bib0031","doi-asserted-by":"crossref","first-page":"1107","DOI":"10.1007\/s40263-021-00839-4","article-title":"Efficacy, retention and tolerability of Everolimus in patients with tuberous sclerosis complex: a survey-based study on patients' Perspectives","volume":"35","author":"Willems","year":"2021","journal-title":"CNS drugs"},{"key":"10.1016\/j.seizure.2026.04.002_bib0032","doi-asserted-by":"crossref","DOI":"10.3390\/jcm12010365","article-title":"Safety of Sirolimus in patients with tuberous sclerosis complex under two years of age-A bicenter retrospective study","volume":"12","author":"\u015amia\u0142ek","year":"2023","journal-title":"J Clin Med"},{"key":"10.1016\/j.seizure.2026.04.002_bib0033","doi-asserted-by":"crossref","first-page":"1358","DOI":"10.7150\/ijms.88022","article-title":"Adverse events of Everolimus in patients with tuberous sclerosis complex treated for renal angiomyolipoma\/subependymal giant cell astrocytoma","volume":"20","author":"Gau","year":"2023","journal-title":"Int J Med Sci"},{"key":"10.1016\/j.seizure.2026.04.002_bib0034","doi-asserted-by":"crossref","DOI":"10.3389\/fcell.2022.973845","article-title":"Long-term efficacy and safety of sirolimus for retinal astrocytic hamartoma associated with tuberous sclerosis complex","volume":"10","author":"Zhang","year":"2022","journal-title":"Front Cell Dev Biol"},{"key":"10.1016\/j.seizure.2026.04.002_bib0035","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1016\/j.seizure.2022.03.003","article-title":"Sirolimus treatment for tuberous sclerosis complex prior to epilepsy: evidence from a registry-based real-world study","volume":"97","author":"Shen","year":"2022","journal-title":"Seizure"},{"key":"10.1016\/j.seizure.2026.04.002_bib0036","article-title":"A multi-centric study assessing safety and efficacy of Everolimus in adult Chinese patients with tuberous sclerosis complex associated renal angiomyolipomas","volume":"12","author":"Wang","year":"2022","journal-title":"Front Oncol"},{"key":"10.1016\/j.seizure.2026.04.002_bib0037","doi-asserted-by":"crossref","first-page":"1066","DOI":"10.1016\/j.ejpn.2018.06.007","article-title":"Short-term safety of mTOR inhibitors in infants and very young children with tuberous sclerosis complex (TSC): multicentre clinical experience","volume":"22","author":"Krueger","year":"2018","journal-title":"Eur J Paediatr Neurol"},{"key":"10.1016\/j.seizure.2026.04.002_bib0038","doi-asserted-by":"crossref","DOI":"10.3389\/fneur.2021.630378","article-title":"TuberOus SClerosis registry to increAse disease awareness (TOSCA) Post-authorisation safety study of Everolimus in patients with tuberous sclerosis complex","volume":"12","author":"Kingswood","year":"2021","journal-title":"Front Neurol"}],"container-title":["Seizure: European Journal of Epilepsy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1059131126000932?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1059131126000932?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,5,14]],"date-time":"2026-05-14T22:21:40Z","timestamp":1778797300000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1059131126000932"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5]]},"references-count":38,"alternative-id":["S1059131126000932"],"URL":"https:\/\/doi.org\/10.1016\/j.seizure.2026.04.002","relation":{},"ISSN":["1059-1311"],"issn-type":[{"value":"1059-1311","type":"print"}],"subject":[],"published":{"date-parts":[[2026,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Adjunctive antiepileptic efficacy and safety study of mTOR inhibitors in children with tuberous sclerosis complex","name":"articletitle","label":"Article Title"},{"value":"Seizure: European Journal of Epilepsy","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.seizure.2026.04.002","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Published by Elsevier Ltd on behalf of British Epilepsy Association.","name":"copyright","label":"Copyright"}]}}